Sales of the GLP-1 receptor antagonist class treatment Trulicity had fallen 30% in 1 year. This is estimated to have been due to the prolonged domestic supply disruptions.

Major insulin products that experienced sporadic supply shortages have experienced a sharp decrease in sales. In the case of Xultophy, its sales, which had surged to KRW 4.8 billion in Q2 fell to KRW 3.1 billion in Q3. In the case of Soliqua, its sales, which had remained at the KRW 2 billion level, sur soared to KRW 4 billion in Q3.

On the other hand, the two other insulins that have been experiencing shortages – Tresiba and Ryzodeg - saw stable sales in Q3 this year.

Trulicity posts record high